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Abstract:
Background: SB 269970, a 5-HT7 receptor antagonist may produce a faster antidepressant-like effect in animal models, than do anti-
depressant drugs, e.g., imipramine. The present work was aimed at examining the effect of single and repeated (14 days) administra-
tion of SB 269970 on the 5-HT7 receptor in the hippocampus.
Methods: The reactivity of 5-HT7 receptors was determined using 5-carboxamidotryptamine (5-CT), which increased the bursting
frequency of spontaneous epileptiform activity in hippocampal slices. Additionally, the effects of SB 269970 administration on the
affinity and density of 5-HT7 receptors were investigated using [
3H]-SB 269970 and the influence of SB 269970 and imipramine on
mRNA expression levels of Gas and Ga12 mRNA were studied using RT-qPCR.
Results: Acute and repeated treatment with SB 269970 led to attenuation of the excitatory effects of activation of 5-HT7 receptors.
Neither single nor repeated administration of SB 269970 changed the mean affinity of 5-HT7 receptors for [
3H]-SB 269970. Re-
peated, but not single, administration of SB 269970 decreased the maximum density of [3H]-SB 269970 binding sites. While admini-
stration of imipramine did not change the expression of mRNAs for Gas and Ga12 proteins after both single and repeated
administration of SB 269970, a reduction in Gas and Ga12 mRNA expression levels was evident.
Conclusions: These findings indicate that even single administration of SB269970 induces functional desensitization of the 5-HT7
receptor system, which precedes changes in the receptor density. This mechanism may be responsible for the rapid antidepressant-
like effect of the 5-HT7 antagonist in animal models.
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Introduction
Serotonin (5-hydroxytryptamine, 5-HT), which acts
as a neurotransmitter and/or a neuromodulator, is in-
volved in a wide spectrum of physiological processes
including sleep, cognition, sensory perception, motor
activity, temperature regulation, appetite, hormone se-
cretion, nociception, and sexual behavior (reviewed
in: [30]). Dysfunctions of the serotonergic system are
thought to be involved in the pathomechanism of de-
pressive disorders. Besides other structures, the hip-
pocampus plays an important role as a target for anti-
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depressant and anxiolytic drugs [72] (reviewed in:
[40, 47]). It has been suggested that a common result
of different types of antidepressant therapies is an en-
hancement of 5-HT neurotransmission within the hip-
pocampus(reviewed in: [9, 19, 27]).
The cellular effects of 5-HT are mediated by up to
14 distinct membrane receptor subtypes that may be
expressed in various amounts in single neurons (re-
viewed in: [28, 29, 55]). Such a diversity permits the
occurrence of different effects of 5-HT, including
both, inhibitory and excitatory influence on neuronal
networks. These mechanisms allow 5-HT to remodel
neuronal excitability in a variety of cell types and
neuronal circuits in a functionally appropriate manner.
In the hippocampus, the most prominent modulatory
effect of 5-HT is a 5-HT1A receptor-mediated reduc-
tion of the excitability of pyramidal cells [1]. Another
5-HT receptor subtype which effectively modulates
neuronal activity is the 5-HT4 receptor whose activa-
tion increases excitability of hippocampal pyramidal
cells [12, 15]. Adaptive modifications of serotonergic
mechanisms modulating the functions of forebrain
structures provide an effective mechanism of antide-
pressant therapies (reviewed in: [8, 36, 39]). In rats,
repeated administration of tricyclic antidepressants
(TCAs) enhances the inhibitory effect of 5-HT1A re-
ceptor activation on the excitability of hippocampal py-
ramidal neurons [6, 13, 17, 35]. Adaptive changes in-
duced by treatment with the TCA imipramine in rat
hippocampus involve attenuation of the excitatory ef-
fect of 5-HT4 receptor activation [7, 74]. Repeated ad-
ministration of selective serotonin reuptake inhibitors
(SSRIs) reduces the effectiveness of hippocampal
5-HT4 receptor activation as well; however, at variance
with the effects of TCA, the sensitivity of hippocampal
5-HT1A receptors remains unchanged after treatment
with SSRIs [7, 13, 14, 62] (reviewed in: [27]).
The 5-HT7 receptor is the latest 5-HT receptor sub-
type to be identified [4, 54]. In the brain, the 5-HT7
receptor is predominantly expressed in the thalamus,
hippocampus, hypothalamus [48] and raphe nuclei
[37]. This receptor has been implicated in mood regu-
lation, circadian rhythmicity and sleep, the distur-
bances of which are evident in the course of affective
disorders (reviewed in: [26, 61]). It has been well es-
tablished that neuronal 5-HT7 receptors activate ade-
nylate cyclase through Gas protein [34, 56]. Interest-
ingly, it has been shown that activation of the 5-HT7A
receptor stimulates AC1 and AC8 Ca2+/calmodulin-
dependent isoforms of adenylate cyclase which are in-
sensitive to Gas in vivo [3]. Moreover, it has been
found that 5-HT7 receptors may also activate Ga12
protein [32]. On a cellular level, activation of the
5-HT7 receptor decreases potassium conductances
and increases the hyperpolarization-activated current
Ih, and thus enhances the excitability of hippocampal
pyramidal cells [2, 5, 65]. All these effects contribute
to the 5-HT7 receptor-mediated facilitation of hippo-
campal population spikes in vivo [38], as well as to
the enhancement of epileptiform activity in disinhib-
ited hippocampal slices in vitro [20, 49, 64].
It has been suggested that the modification of 5-HT7
receptor activity resulting from chronic treatment with
antidepressants may represent a mechanism underlying
the therapeutic effect of these drugs [57] (reviewed in:
[24, 26]). It is noteworthy that several psychotropic
drugs exhibit high affinity for 5-HT7 receptors [50, 52,
56, 59] (reviewed in: [33]). It has also been shown that
certain antidepressants may exert some effects by act-
ing directly on the 5-HT7 receptor [46].
Recent studies have demonstrated a synergistic in-
teraction between serotonin receptors antagonists and
several antidepressant drugs [53, 67], including the
specific 5-HT7 receptor antagonist SB 269970 [11,
70]. In animal models, inactivation or blockade of the
5-HT7 receptor has been shown to induce antidepres-
sant-like behavior [21, 25, 69]. Chronic treatment
with antidepressants has also been shown to modify
the reactivity of 5-HT7 receptors. The downregulation
of the 5-HT7 receptor has been found to take place in
rat suprachiasmatic nucleus of the hypothalamus after
chronic treatment with TCAs including imipramine,
and the SSRI – fluoxetine [46, 58]. Our earlier study
indicated attenuation of the effects of activation of rat
hippocampal 5-HT7 receptors after treatment with the
TCA imipramine and the SSRI citalopram [64]. These
findings support the hypothesis that the 5-HT7 receptor
may be a target for the action of antidepressants drug.
Moreover, blockade of this receptor opens up good
possibilities for the treatment of depression [43] (re-
viewed in: [24, 40, 44]). It is widely known that the re-
sponse to treatment with conventional antidepressants
may be delayed for several weeks.
Previously, our electrophysiological study showed
that repeated (14 times), but not single, imipramine
administration diminished the reactivity of the 5-HT7
receptor [64]. We also demonstrated that chronic
treatment with imipramine modified neither the affin-
ity of 5-HT7 receptors to [3H]-SB 269970 nor the den-
sity of those receptors [63].
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Recent research has shown that acute administra-
tion of SB 269970, a 5-HT7 receptor antagonist, short-
ens immobility time in the forced swim test [68].
Moreover, blockade of the 5-HT7 receptor may pro-
duce a faster antidepressant effect than do contempo-
raryantidepressant drugs [42].
Since only the effect of acute administration of SB
269970 has been investigated so far (mainly in behav-
ioral studies), the present work was aimed at examin-
ing the effect of acute and prolonged treatment with
SB 269970 on the reactivity of the 5-HT7 receptor in
the hippocampus using biochemical and electro-
physiological methods. We studied the influence of
the blockade of 5-HT7 receptors on their affinity and
density. The 5-HT7 receptor may be coupled to two
different G proteins: Gas and Ga12 (reviewed in:
[71]). For this reason we also examined the effect of
SB 269970 on Gas and Ga12 mRNAs expression and
compared the impact of 5-HT7 receptor blockade with
the effect of a the classic tricyclic antidepressant
(TCA) imipramine.
Materials and Methods
Drugs
5-Carboxamidotryptamine maleate (5-CT), (2R)-1-
[(3-hydroxyphenyl)sulfonyl]-2-[2-(4-methyl-1-piperidinyl)
ethyl]pyrrolidine hydrochloride (SB 269970) and
N-{2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl}-N-2-
pyridinylcyclohexanecarboxamide (WAY 100635)
were obtained from Sigma-Aldrich. [3H]-SB 269970
(62.7 Ci/mol) was purchased from Moravek Bio-
chemicals, Brea, CA.
Treatment of animals
The experimental procedures were approved by the
Animal Care and Use Committee at the Institute of
Pharmacology, PAS and were carried out in accor-
dance with the “Principles of laboratory animal care”
(NIH publication no. 85-23, revised 1985) and the na-
tional law. Male Wistar rats, weighing approx. 100 g
at the beginning of the experiment, were housed in
groups on a controlled light/dark cycle (the light on:
7:00–19:00) and had free access to standard food and
tap water. The rats received SB 269970 (1.2 mg/kg,
ip, dissolved in 0.9% NaCl, volume: 1 ml/kg) either
repeatedly for 14 days, or as a single injection. In the
latter group, single administration of SB 269970 was
preceded by 13 daily injections of 0.9% NaCl. The
animals of the control group received 0.9% NaCl
once daily for 14 days.
Two separate experimental groups of the animals
received imipramine (10 mg/kg, ip, dissolved in 0.9%
NaCl, volume: 1 ml/kg) once daily for 14 consecutive
days, or as a single injection. In the latter group single
administration of imipramine was preceded by 13
daily injections of 0.9% NaCl. The animals of the
control group for imipramine experiments received
0.9% NaCl once daily for 14 days.
The rats were killed by decapitation two days after
the last drug administration; then their brains were re-
moved and used for further analyses.
Slice preparation, electrophysiological
recording and data analysis
The brains were immersed in an ice-cold artificial
cerebrospinal fluid (ACSF) composed of (in mM):
NaCl (124), KCl (5), CaCl2 (2.5), MgSO4 (1.3),
KH2PO4 (1.25), NaHCO3 (24) and D-glucose (10).
ACSF was bubbled with a mixture of 95% O2/5%
CO2. After dissection, the hippocampus was cut into
transverse slices (400 µm thick) using a vibrating mi-
crotome (Leica, USA).
The slices were left to recover in the holding cham-
ber at 32 ± 0.5°C, for 1–6 h. A single slice was then
transferred to the recording chamber of a submerged
type and was superfused (1.5 ml/min) with a warmed
(32 ± 0.5°C), modified ACSF, in which [NaCl] was
raised to 132 mM and [KCl] was lowered to 2 mM,
devoid of Mg2+ ions. Glass micropipettes filled with
2 M NaCl (1–4 MW) were used to record activity
from the pyramidal layer of the CA3 area. Spontane-
ous epileptiform bursts were amplified (Axoprobe 2,
Axon Instruments, USA), band-pass filtered (1 Hz –
10 kHz), A/D converted, stored on a PC (1401 inter-
face with Signal 2 software, CED, UK) and analyzed
off-line [66]. Drug effects were assessed in terms of
changes in bursting frequency (± SEM) and by com-
paring the average frequency over 6–10 min after the
beginning of 5-carboxamidotryptamine maleate (5-CT)
application to the baseline values (see Fig. 1). The
data from treated and control rats were also compared
using a paired t-test.
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Membranepreparation and saturation analysis
Rat hippocampi were immediately frozen on dry ice
and stored at –80°C. The membranes were prepared
according to the method described previously [10] by
homogenizing (Ultra Turrax) the tissue in 20 volumes
(based on wet weight) of 50 mM Tris-HCl (pH = 7.4 at
37°C). Following centrifugation (50,000 × g, 12 min,
4°C) the pellets were resuspended in the same me-
dium and incubated at 37°C for 15 min. After a fur-
ther three centrifugation and resuspension steps, the
pellets were stored at –80°C for further analysis. Satu-
ration binding assays were performed using [3H]-SB
269970 according to the method described by Thomas
et al. [60]. On the day of the experiment, the mem-
branes (approx. 15 mg tissue/tube) were defrosted,
suspended in a Tris-HCl buffer (50 mM, pH = 7.4 at
37°C) containing CaCl2 (4 mM), pargyline (0.1 mM)
and ascorbic acid (1 mM) and were incubated with
[3H]-SB 269970 (eight concentrations within a range
of: 0.2–11 nM) for 60 min at 37°C. The non-specific
binding was determined using 10 µM 5-HT. The incu-
bation was terminated by passing through Whatman
GF/B filters, followed by immediate washing with an
ice-cold Tris-HCl buffer. The bound radioactivity re-
maining on the filters was assayed by liquid scintilla-
tion spectroscopy (Beckman L SM 6500). All the as-
says were performed in triplicate in three separate ex-
periments. The binding data were analyzed using
non-linear regression (GraphPad Software Inc., San
Diego, USA) generating Kd and Bmax values.
RNA isolation and RT-qPCR
A frozen hippocampal tissue was placed in the Lysis
Buffer (4.5 M guanidine-HCl, 100 mM sodium phos-
phate, pH 6.6; Roche, Germany) at a volume of
0.4 ml/20 mg of the tissue, and was homogenized by
high-speed shaking (30/s) in plastic tubes with stain-
less steel beads in the TissueLyserII apparatus (Qia-
gene, USA). Total RNA was purified using a High
Pure RNA Tissue Kit (Roche, Germany) according to
the manufacturer’s protocol. The quantity of RNA
was determined spectrophotometrically at 260 nm and
260/280 nm (ND/1000 UV/Vis; Thermo Fisher Nano-
Drop, USA) and its quality was confirmed by electro-
phoresis on agarose gel.
A two-step reaction: a reverse transcription (RT)
and a quantitative polymerase chain reaction (qPCR)
was run in the Chromo4 RealTime PCR Instrument
(MJ Research, USA). Five hundred nanograms of to-
tal RNA and 2 U of RNase inhibitor (Fermentas,
Lithuania) were incubated for 5 min at 65°C and
chilled on ice. An RT reaction was performed at a fi-
nal volume of 20 µl of the reaction mixture containing
1× AMV reverse transcriptase buffer (Finnzymes,
Finland), 1 mM deoxynucleotide-3-phosphate mixture
(dNTP, Fermentas), 10 µM universal primer oligo
(dT), 2 U of the ribonuclease inhibitor (Ribolock, Fer-
mentas, Lithuania), 10 U of AMV reverse transcrip-
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Fig. 1. The influence of administration of the 5-HT7 receptor
antagonist SB 269970 on the 5-HT7 receptor-mediated excitatory
effect of 5-CT in ex vivo hippocampal slices. (A) Spontaneous
bursting activity recorded in the CA3 area in a representative
experiment. (B) A dose-response curve for the effect of 5-CT on the
bursting activity in control preparations (the mean ± SEM). (C) Single
(labeled: SB 1´) and repetitive (labeled: SB 14´) administration of SB
269970 resulted in attenuation of the excitatory effect of 50 nM 5-CT
compared to slices obtained from untreated rats (CON). *** p <
0.001, t-test
tase. The RT reaction was carried out at 42°C for 90
min and was followed by a denaturation step at 70°C
for 10 min. The products of RT reaction were ampli-
fied using TaqMan probes and primers for the Gas,
Ga12 and hypoxanthine-guanine phosphoribosyltrans-
ferase (HPRT) (Assays ID: Rn00569454_m1 and
Rn00578965_m1 and Rn01527840_m1, respectively)
(Applied Biosystems) and a FastStart Universal Probe
Master (Rox) kit (Roche, Germany). Amplification
was carried out at a total volume of 10 µl of the reac-
tion mixture containing 1× FastStart Universal Probe
Master (Rox) mix (Roche, Germany), 50 ng of cDNA
as a PCR template, 900 nM TaqMan forward and re-
verse primers and 250 nM hydrolysis probe labeled
with the fluorescent reporter dye FAM at the 5’-end,
and a quenching dye at the 3’-end. The qPCR was run
with the following profile: 1 cycle at 50°C for 2 min,
1 cycle at 95°C for 10 min and 40 cycles each at 95°C
for 15 s and 60°C for 1 min. The threshold value (Ct)
for each sample was set in the exponential phase of
PCR, and the DD Ct method was used for data analy-
sis. HPRT was used as reference gene, and its expres-
sion was observed at a constant level in each experi-
mentalgroup of the animals.
Statistical analysis
All the values are given as the mean ± standard error
of the mean (SEM). A statistical analysis of the data
was performed using Statistica 8.0 software (StatSoft,
Tulsa, USA) and a one-way analysis of variance
(ANOVA), followed by Fisher’s Least Significant
Difference (LSD) test, p < 0.05 was considered statis-
tically significant. The data from treated and control
rats were also compared using a paired t-test.
Results
Effect of SB 269970 administration on bursting
activity
Epileptiform bursting of a regular frequency occurred
within 15–20 min after the placement of slices in
a nominally Mg2+-free, modified ACSF. Individual
bursting events consisted of an initial, population
spike-like waveform (1–2 mV in amplitude), which
was followed by a slower, positive-going wave. As re-
ported previously, the application of 5-CT to the
ACSF in the presence of WAY 100635 resulted in
a dose-dependent, 5-HT7 receptor-mediated increase
in the bursting frequency which reached its maximum
between 6–10 min after the start of 5-CT application
[49, 64]. Single administration of SB 269970 did not
change the mean baseline bursting frequency, which
did not differ from that recorded in slices obtained
from the control groups of animals receiving the vehi-
cle (Tab. 1). However, repeated administration of SB
269970 resulted in a ca. twofold decrease in the base-
line bursting frequency (Tab. 1).
To investigate the effects of SB 269970 administra-
tion on the 5-HT7 receptor-mediated enhancement of the
bursting activity, 50 nM 5-CT was applied to the ACSF.
As shown in Figure 1C, the magnitude of the 5-CT-
induced effect was attenuated in hippocampal slices pre-
pared from the animals receiving single as well as re-
peated doses of the 5-HT7 receptor antagonist.
Effect of SB 269970 administration on the
affinity and density of 5-HT
7
receptors
Neither single nor repeated administration of SB
269970 changed the mean affinity of 5-HT7 receptors
for [3H]-SB 269970. After single administration, the
maximum density (Bmax) of the receptors also re-
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Tab. 1. The influence of single (SB 1×) and repeated (SB 14×) ad-
ministration of SB 269970 on the mean (± SEM) basal discharge fre-
quency in ex vivo hippocampal slices
Basal discharge
frequency [Hz]
n
CON 0.116 ± 0.0189 46
SB 1× 0.113 ± 0.0146 30
SB 14× 0.0556 ± 0.0072* 32
* p < 0.013, SB 14× vs. control
Tab. 2. The influence of single (SB 1×) and repeated (SB 14×) admini-
stration of SB 269970 on the mean (± SEM) affinity (pKd) and the maxi-
mum density (Bmax; ± SEM) of 5-HT7 receptors in rat hippocampus
CON SB 1´ SB 14´
pK
d
0.8.99 ± 0.06 8.78 ± 0.05 9.04 ± 0.06
B
max
[pM/mg] 0.14 ± 0.003 0.13 ± 0.005 0.09 ± 0.004#
# p < 0.001, SB 14× vs. control
mained unchanged (Tab. 2). On the contrary, after 14
injections of the 5-HT7 receptor antagonist, the value
ofBmax significantly decreased (Tab. 2).
Effect of imipramine and SB 269970 on
G-protein mRNA expression
Neither single nor repeated administration of imi-
pramine induced changes in the expression of
mRNAs for the G proteins studied (Figs. 2A2, B2). In
contrast, SB 269970 injections caused a statistically
significant reduction in Gas and Ga12 mRNA expres-
sion levels. Those effects were evident after both sin-
gle and repeated administration of the 5-HT7 receptor
antagonist (Figs. 2A1, B1).
Discussion
The major finding of this study is that treatment with
a specific 5-HT7 receptor antagonist decreases the re-
activity of the 5-HT7 receptor, which can bee seen af-
ter both single and repeated administration. For the
last several years, a number of studies have attempted
to evaluate the role of the 5-HT7 receptor in depres-
sive disorders, as well as in the action of antidepres-
sant drugs. It has recently been shown that the block-
ade of the 5-HT7 receptor synergistically potentiates
the effect of clinically used antidepressants in an ani-
mal model of depression [70]. Moreover, it has been
demonstrated that the antagonist of the 5-HT7 recep-
tor per se can exert antidepressive action [42]. The
above data suggest that the blockade of the 5-HT7 re-
ceptor may play a role in the antidepressive action,
and that some antidepressants can exert their thera-
peutic effect via blockade of the 5-HT7 receptor or via
a decrease in 5-HT7 receptor reactivity. The results of
our earlier study showing that chronic treatment with
the antidepressants of different classes may decrease
the reactivity of the 5-HT7 receptor seem to support
this assumption [64].
The present study provides evidence for attenua-
tion of the excitatory effect of activation of the 5-HT7
receptor after treatment with SB 269970. In contrast
to several antidepressants tested so far, this effect oc-
curred not only after repeated treatment, but already
after single injection of the antagonist. The swift ac-
tion of SB 269970 on the reactivity of the 5-HT7 re-
ceptor is in line with the results obtained by other
authors. Mnie-Filali and coworkers [42] found a re-
duced 5-HT1A and/or 5-HT7 receptor responsiveness
in the dorsal raphe nucleus (DRN) after one week of
5-HT7 receptor blockade. To achieve a similar effect
for standard antidepressants, at least 21-day treatment
is necessary. Thus, the pharmacological blockade of
5-HT7 receptors produces a considerably faster
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Fig. 2. The influence of treatment with
the 5-HT7 receptor antagonist SB
269970 and imipramine on the expres-
sion of Gas and Ga12 mRNA in the
hippocampus. (A) The Gas mRNA
expression level after single (1×) or
repeated (14´) administration of SB
269970 (labeled SB; A1) and imipra-
mine (labeled: IMI; A2). (B) The Ga12
mRNA expression level after single
(1×) or repeated (14×) administration
of SB 269970 (labeled SB; B1) and
imipramine (labeled: IMI; B2); ** p <
0.001, *** p < 0.0001 vs. vehicle (either
NaCl or water); ANOVA, n = 9–10 per
group
antidepressant-like response than do most antidepres-
sant drugs [42]. Such a phenomenon may occur as
a result of either an increased 5-HT7 receptor activa-
tion or activation of other 5-HT receptors by an ele-
vated extracellular 5-HT level due to the enhanced ac-
tivity of serotonergic neurons. It has been shown that
the blockade of 5-HT7 receptors increases 5-HT ra-
phe–hippocampus transmission [11]. Enhancement of
5-HT transmission in such projection areas as the dor-
sal hippocampus after 1 week of SB 269970 admini-
stration has also been reported by other researchers
[42]. On the other hand, some authors have found that
the 5-HT7 receptor antagonist SB 269970 signifi-
cantly inhibits 5-HT efflux [51]; however, other in-
vestigators have shown that inhibition of 5-HT release
is likely to be mediated by 5-HT7 receptor agonists
[22]. The mechanism of control of DRN neuronal ac-
tivity by 5-HT7 receptors seems to be indirect, since
the regulation of DRN activity via the 5-HT7 receptor
is tetrodotoxin-sensitive [23]. This may suggest that
5-HT7 receptors are not directly localized on 5-HT
neurons, but rather on GABAergic and/or glutamater-
gic ones [23, 45]. It is speculated that the local gluta-
matergic, GABAergic and serotonergic circuitry in
the raphe nuclei forms an excitatory-inhibitory con-
nection by which incoming excitatory signals are con-
verted into an inhibitory output projecting to various
brain areas such as, e.g., cerebral cortex, striatum,
hippocampusor hypothalamus [23, 45].
Alternatively, the decreased reactivity of hippocam-
pal 5-HT7 receptors may result from a direct interaction
between SB 269970 molecules and the receptor. The
molecular mechanism underlying the observed at-
tenuation of the excitatory effect of activation of the
5-HT7 receptor after treatment with SB 269970 may
be related either to the decreased receptor density or
modifications in the capacity of the receptor to acti-
vate G protein, changes in G protein expression or
phosphorylation, or modifications at the level of ef-
fectors (reviewed in: [18, 27]). The downregulation of
the 5-HT7 receptor, related to chronic treatment with
a variety of antidepressants including imipramine and
fluoxetine, was previously found to occur in the su-
prachiasmatic nucleus of rat hypothalamus [46, 58],
where such treatment reduced 5-HT7 receptor density
by approx. 30%, without changing the receptor affin-
ity, though.
As mentioned above, the SB 269970-induced de-
crease in the reactivity of rat CA1 hippocampal neu-
rons to 5-HT7 receptor activation may also be related
to modifications in the transduction pathway, includ-
ing changes in the receptor density and/or in the cou-
pling of the receptor to G protein. In fact, our data
demonstrate that both single and repeated administra-
tion of SB 269970 reduces the level of mRNA of
5-HT7 receptor coupled G proteins (Gas and Ga12). It
should be stressed that these changes are specific to
the application of the 5-HT7 antagonist, since imi-
pramine administered once or repeatedly does not al-
ter the level of the mRNAs. We previously showed
that repeated administration of imipramine (lasting 14
days) decreased the responsiveness of 5-HT7 recep-
tors in the CA3 area and that imipramine did not mod-
ify the mean basal bursting frequency [64]. However,
the present data show that repeated administration of
SB 269970 decreases the mean basal bursting fre-
quency, which is lower when compared to the activity
recorded in slices obtained from control animals. The
most likely explanation of such an effect is reduction
of excitatory synaptic transmission. The above results
suggest that changes induced by chronic or prolonged
administration of SB 269970 depend, at least in part,
on mechanisms different from those underlying
changes caused by imipramine. It has been demon-
strated that activation of 5-HT7 receptors increases
neurite outgrowth in hippocampal neurons [32]. Both
Gas and Ga12 proteins can regulate cellular morphol-
ogy by activating different signaling cascades. Gas
protein-mediated morphogenic effects are produced
by either modulation of cAMP concentration [16] or
direct binding of Gas protein to the cytoskeleton [73].
The downstream effectors of Ga12 protein, which me-
diate changes in the actin cytoskeleton, are members
of the Rho family of small GTPases, including RhoA,
Rac1 and Cdc42 (reviewed in: [31]). The major func-
tional effects of this pathway, including actin reor-
ganization and the formation of neurite-like protru-
sions, are mediated by the activation of Cdc42 [32]. It
is proposed that activation of the 5-HT7 receptor by
Gas and Ga12 proteins may stimulate glutamatergic
synaptic transmission by a positive influence on
a number of functional synapses. Hence, the pro-
longed blockade of the 5-HT7 receptor, resulting in
a decreased expression of Gas and Ga12 proteins
might account for the observed reduction of glutama-
tergic transmission.
All in all, the current study shows that the blockade
of the 5-HT7 receptor by SB 269970 leads to func-
tional desensitization of the 5-HT7 receptor system at
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a level of its reactivity and effector proteins, although
changes in the receptor density occur after chronic
treatment with the antagonist only. The phenomenon
of 5-HT7 receptor system downregulation may be an
important factor in the mechanism of the antidepres-
sant effect of the 5-HT7 antagonist, as well as in the
modulation of reactivity of other neurotransmitter
systems.
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